PMID- 16461305
OWN - NLM
STAT- MEDLINE
DCOM- 20060706
LR  - 20220309
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Linking)
VI  - 91
IP  - 2
DP  - 2006 Feb
TI  - Differential effect of the low-molecular-weight heparin, dalteparin, and 
      unfractionated heparin on microvascular endothelial cell hemostatic properties.
PG  - 207-14
AB  - BACKGROUND AND OBJECTIVES: Heparins, including unfractionated heparin (UFH) and 
      low-molecular-weight heparins (LMWH), are glycosaminoglycans that are largely 
      used as anti-thrombotic drugs. While the mechanisms of their anticoagulant 
      actions in blood have been extensively studied, their effects on the hemostatic 
      properties of the endothelium are still under investigation. The aim of this 
      study was to compare the antithrombotic effects of a LMWH, i.e. dalteparin, with 
      UFH on both microvascular (human microvascular endothelial cells [HMEC-1]) and 
      macrovascular (human umbilical vein endothelial cells [HUVEC]) endothelial cells. 
      DESIGN AND METHODS: Endothelial cells were incubated with dalteparin or UFH and 
      exposed to an inflammatory stimulus (i.e. lipopolysaccharide [LPS]). The 
      following parameters were evaluated: tissue factor (TF procoagulant activity, 
      antigen and mRNA), tissue factor pathway inhibitor (TFPI), and thrombomodulin 
      (TM). RESULTS: In HMEC-1 and HUVEC, both heparins inhibited LPS-induced 
      endothelial cell TF expression. However, in HMEC-1, dalteparin was significantly 
      more effective than UFH. Both heparins increased TFPI antigen release in HMEC-1 
      and HUVEC. Dalteparin also reversed LPS-induced reduction of TM in HMEC-1, while 
      UFH did not. INTERPRETATION AND CONCLUSIONS: These data show that both dalteparin 
      and UFH suppress inflammatory-mediated TF expression and increase the 
      anticoagulant properties of macro- and micro-vascular endothelial cells. However, 
      dalteparin has significantly greater effects than UFH in the microvascular 
      endothelium, a site that plays a central role in many processes involved in 
      inflammation and thrombosis.
FAU - Vignoli, Alfonso
AU  - Vignoli A
AD  - Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 
      24128 Bergamo, Italy.
FAU - Marchetti, Marina
AU  - Marchetti M
FAU - Balducci, Donatella
AU  - Balducci D
FAU - Barbui, Tiziano
AU  - Barbui T
FAU - Falanga, Anna
AU  - Falanga A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
EIN - Haematologica. 2006 May;91(5):620
CIN - Haematologica. 2006 Feb;91(2):149a. PMID: 16461295
MH  - Cells, Cultured
MH  - Dalteparin/pharmacology
MH  - Endothelium, Vascular/cytology/*drug effects
MH  - Hemostasis/*drug effects
MH  - Heparin/*pharmacology
MH  - Heparin, Low-Molecular-Weight/pharmacology
MH  - Humans
MH  - Microcirculation/*drug effects
EDAT- 2006/02/08 09:00
MHDA- 2006/07/11 09:00
CRDT- 2006/02/08 09:00
PHST- 2006/02/08 09:00 [pubmed]
PHST- 2006/07/11 09:00 [medline]
PHST- 2006/02/08 09:00 [entrez]
PST - ppublish
SO  - Haematologica. 2006 Feb;91(2):207-14.